ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
36 announcements
Invicta Diagnostic Limited reported changes to its leadership and audit team, including a director's re-appointment, a designation change, and a new secretarial auditor.
Invicta Diagnostic Limited conducted its 3rd Annual General Meeting on September 19, 2026. The proceedings detailed company operations and future financial targets.
Board approved business outlook and forward-looking guidance for the 3rd AGM on 19 September 2026. Company targets consolidated revenue of ₹45–50 crore with ~25% EBITDA margin.
Invicta's subsidiaries commenced operations at two diagnostic centres in Shegaon and Pune. Investment is Rs. 70 lakhs for CT scan and pathology services.
Invicta Diagnostic approved the notice for its 3rd Annual General Meeting scheduled for 19th September 2026, alongside adoption of financial reports and director appointments.
Invicta Diagnostic Limited is selling its associate entity, MSCRIBEIT INFOTECH LLP, for a cash consideration of Rs. 50,000. The transaction is expected to conclude by March 2027.
Invicta Diagnostic Limited announced the resignations of Executive Director Rohit Prakash Srivastava and Manager Konica Rohit Srivastava. Additionally, Director Sanket Vinod Jain was redesignated as Executive Director.
Invicta Diagnostic Limited announced management changes, including the appointment of Dr. Sanket Vinod Jain as Managing Director, and the divestment of its stake in MSCRIBEIT Infotech LLP.
Invicta Diagnostic Limited has scheduled a board meeting on July 29, 2026. The agenda includes board appointments and the proposed sale of its stake in MSCRIBEIT INFOTECH LLP.
Invicta Diagnostic Limited reported a management change in its subsidiary, Porteus Pathogenius LLP, involving the appointment of Mayur Shivdas Kasat following Vishwajeet Arvind Burungale's stake sale.
Invicta Diagnostic Limited informed the exchange of a partner change in its step-down subsidiary, Porteus Pathogenius LLP. Mr. Mayur Shivdas Kasat has been inducted as a partner.
Invicta Diagnostic started commercial operations at its Pune centre. This expands its network to ten diagnostic centres and one centralized laboratory.
Invicta Diagnostic started commercial operations at its Pune Centre via subsidiary Porteus Medical LLP. The project required an investment of ₹0.0416 Crore.
Invicta Diagnostic Limited completed the incorporation of a new diagnostics LLP. The execution of the initial partnership agreement marks the entity's formal establishment.
Invicta Diagnostic Limited incorporated a new step-down subsidiary, Porteus Pathogenius LLP, with ₹0.01 Crore capital. The entity will expand the group's diagnostics and pathology service footprint.
Invicta Diagnostic Limited reported zero deviation in the utilization of ₹28.12 Crore IPO proceeds. The Audit Committee reviewed and confirmed the deployment status.
Invicta Diagnostic reported standalone total income of ₹21.41 Crore for FY26. The board approved audited results with an unmodified opinion from statutory auditors.
Invicta Diagnostic (PC Diagnostics) reported FY26 revenue of ₹33.04cr with 31.63% EBITDA margins. Strategy focuses on Maharashtra-based expansion of advanced radiology hubs and strategic acquisitions like Vinchurkar Diagnostics.
Invicta Diagnostic (PC Diagnostics) reported FY26 Total Income of ₹33.04 Cr with 31.63% EBITDA margin. Strategy focuses on radiology-led growth in the Mumbai Metropolitan Region (MMR).
Invicta Diagnostic launched tele-radiology services in the United States, marking its international expansion. This move enhances global diagnostic reporting and patient care delivery.
Invicta Diagnostic Limited reported a ₹33.04 Crore total income for FY26 with EBITDA margins exceeding 30%. The company is expanding across Maharashtra through strategic acquisitions and JVs.
Invicta Diagnostic Ltd reported revenue from operations of ₹15.4 Cr and net profit of ₹0.8 Cr for H2 FY26.
Invicta Diagnostic Limited reported audited financial results for fiscal year 2026. The Board approved standalone and consolidated statements showing steady performance across its diagnostic centers.
Invicta Diagnostic Limited completed the sale of its 47% stake in Porteus Medical LLP. This transaction finalizes the divestment for a consideration of ₹47,000.
Invicta Diagnostic Limited scheduled a board meeting on May 18, 2026, to approve audited annual financial results. Trading window remains closed until June 02, 2026.
Invicta Diagnostic Limited appointed M/s. Shrenik Nagaonkar and Associates as Secretarial Auditor for five years. The firm brings 19 years of governance and capital markets expertise.
Invicta Diagnostic Limited appointed M/s. Shrenik Nagaonkar & Associates as Secretarial Auditor for five years. This ensures statutory compliance with Companies Act and SEBI regulations.
Invicta Diagnostic Limited acquired a 51% stake in Vinchurkar Diagnostics for ₹7.60 Crore. This marks the completion of the first tranche of the proposed acquisition.
Invicta Diagnostic Limited announced the results of its Extra Ordinary General Meeting held on April 17, 2026. Shareholders approved 16 resolutions, including the regularization of Mr. Rohit Prakash Srivastava as Whole-Time Director and various material related party transactions. All resolutions were passed with the requisite majority via remote e-voting and electronic voting during the meeting.
Invicta Diagnostic Limited has redesignated Rohit Prakash Srivastava as Whole Time Director Finance for a 5-year term, effective April 17, 2026. Srivastava brings over 19 years of experience across healthcare and finance. This appointment formalizes his executive leadership role within the company's senior management team.